Carregant...
State‐of‐the‐art treatment of systemic lupus erythematosus
As glucocorticoids and immunosuppressive drugs are non‐specific therapeutic agents that cause many adverse reactions, the development of biologicals aiming to control specific molecular targets is anticipated for the treatment of systemic lupus erythematosus (SLE). The antibody targeting B cell‐acti...
Guardat en:
| Publicat a: | Int J Rheum Dis |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7187183/ https://ncbi.nlm.nih.gov/pubmed/32134201 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1756-185X.13817 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|